PLX: Elfabrio Estimates Up
Protalix is a clinical and commercial pharmaceutical company using its proprietary ProCellEx plant-based expression system to pro duce thera...
92 Views
Primer: Protalix BioTherapeutics (PLX US) - Aug 2026
The recent approvals of Elfabrio in the US and EU for Fabry disease represent a pivotal commercial inflection point, with revenue potential...
110 Views
PLX: Chiesi Milestone Received
Protalix is a clinical and commercial pharmaceutical company using its proprietary ProCellEx plant-based expression system to pro duce thera...
96 Views
PLX: 2025 Full Year Results
Protalix is a clinical and commercial pharmaceutical company using its proprietary ProCellEx plant-based expression system to pro duce thera...
139 Views
PLX: CHMP Delivers Positive Opinion
Protalix is a clinical and commercial pharmaceutical company using its proprietary ProCellEx plant-based expression system to pro duce thera...
133 Views